Revance Therapeutics Inc (NASDAQ: RVNC) stock suffered a major decline of -17.0% on 11/9/23. The shares closed at $6.91. The stock has been extremely weak relative to the market over the last nine months and has declined -12.9% during the last week.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, RVNC is expected to be Value Creation neutral.
Revance Therapeutics has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects highly consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Revance Therapeutics has a very low Appreciation Score of 0 and a very low Power Rating of 0, and the Lowest Value Trend Rating results.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment